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GRACILE (growth retardation, aminoaciduria, cholestasis, iron overload, lactacidosis, and early death) syndrome
is a recessively inherited lethal disease characterized by fetal growth retardation, lactic acidosis, aminoaciduria,
cholestasis, and abnormalities in iron metabolism. We previously localized the causative gene to a 1.5-cM region
on chromosome 2q33-37. In the present study, we report the molecular defect causing this metabolic disorder, by
identifying a homozygous missense mutation that results in an S78G amino acid change in the BCS1L gene in
Finnish patients with GRACILE syndrome, as well as five different mutations in three British infants. BCS1L, a
mitochondrial inner-membrane protein, is a chaperone necessary for the assembly of mitochondrial respiratory
chain complex III. Pulse-chase experiments performed in COS-1 cells indicated that the S78G amino acid change
results in instability of the polypeptide, and yeast complementation studies revealed a functional defect in the
mutated BCS1L protein. Four different mutations in the BCS1L gene have been reported elsewhere, in Turkish
patients with a distinctly different phenotype. Interestingly, the British and Turkish patients had complex III de-
ficiency, whereas in the Finnish patients with GRACILE syndrome complex III activity was within the normal range,
implying that BCS1L has another cellular function that is uncharacterized but essential and is putatively involved
in iron metabolism.
Introduction
GRACILE (growth retardation, aminoaciduria, cholesta-
sis, iron overload, lactacidosis, and early death) syndrome
(MIM 603358) is a metabolic disorder with an autosomal
recessivemode of inheritance (Fellman et al. 1998;Rapola
et al. 2002). Affected infants are severely growth retarded,
the average birth weight being only 1,700 g at term. Pa-
tients develop fulminant lactic acidosis during the first
day of life, with an average arterial blood pH of 7.0. They
also have nonspecific aminoaciduria, cholestasis, and iron
overload, including hemosiderosis of the liver, increased
serum ferritin concentration, hypotransferrinemia with
increased transferrin saturation, and free plasma iron. No
Received June 7, 2002; accepted for publication July 9, 2002; elec-
tronically published September 5, 2002.
Address for correspondence and reprints: Dr. Leena Peltonen, De-
partment ofMolecularMedicine, Biomedicum,National PublicHealth
Institute, Haartmaninkatu 8, PO Box 104, FIN-00290 Helsinki, Fin-
land. E-mail: leena.peltonen@ktl.fi
Nucleotide sequence data reported herein are available in the DDBJ/
EMBL/GenBank databases; for details, see the Electronic-Database
Information section of this article.
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7104-0015$15.00
deficiency in respiratory chain oxygen consumption or
enzyme activity has been demonstrated in patients, and
they do not have neurological abnormalities or dys-
morphic features. Despite intensive care and alkali ther-
apy, about half of the infants die during the first days of
life, and the remainder within 4 mo of life.
GRACILE syndrome belongs to the Finnish disease
heritage (Norio et al. 1973; Peltonen et al. 1999). On
the basis of 13 cases diagnosed in 1991–2000, the in-
cidence is1/47,000 in Finland. We previously mapped
the GRACILE locus to a 1–1.5-cM region between
markers D2S2179 and D2S2244 on chromosome 2q33-
37 (fig. 1A). The disease locus was initially identified
via a genome scan, and the critical chromosomal region
was restricted through use of linkage disequilibrium and
haplotype analyses in 10 Finnish families (Visapa¨a¨ et
al. 1998). All families carried the same ancestral hap-
lotype, indicating one founder mutation in Finland. The
physical interval of the critical GRACILE region is 1.4
Mb in the latest NCBI human genome assembly (Map-
Viewer, May 2002, at the Human Genome at NCBI
Web site), including as many as 28 known genes and
several predicted hypothetical genes. We recently ex-
cluded ABCB6, a gene encoding a mitochondrial pro-
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Figure 1 A, Critical GRACILE region. The locations of the two functionally and positionally promising candidate genes, BCS1L and
ABCB6, are shown in relation to the markers demonstrating linkage disequilibrium in GRACILE chromosomes. The marker order and distances
are presented as in the NCBI MapViewer, May 2002. B, Genomic structure of the BCS1L gene. The sizes of the exons and introns are indicated
in base pairs. The BCS1L mutations reported here (in Finnish and British patients) are indicated above the figure, and the BCS1L mutations
described elsewhere (de Lonlay et al. 2001) are marked below. The sizes of the first exon and the first intron (marked with asterisks) vary
because of alternative splicing. C, The BCS1L polypeptide of 419 amino acid residues. The numbers indicate the polypeptide regions encoded
by distinct exons of the BCS1L gene. Residues 9–32 correspond to the transmembrane region of the yeast BCS1p protein (Fo¨lsch et al. 1996).
Residues 224–344 represent the conserved AAA domain, according to CD-Search (Marchler-Bauer et al. 2002) at the NCBI BLAST service.
tein involved in iron homeostasis, mitochondrial res-
piratory function, and maintenance of the stability of
mtDNA (Mitsuhashi et al. 2000), as the causative gene
for this disease (Visapa¨a¨ et al. 2002). Another posi-
tionally and functionally promising candidate gene,
BCS1L, encodes a mitochondrial protein that functions
as a chaperone in the assembly of complex III (cyto-
chrome bc1 complex) of the mitochondrial respiratory
chain.
Complex III consists of 11 subunits: core proteins I
and II, six small subunits, and three polypeptides involved
in electron transport: cytochrome b, cytochrome c1, and
the Rieske FeS protein. Cytochrome b is encoded by
mtDNA, whereas the other subunits are encoded by nu-
clear genes. Several sporadic heteroplasmic cytochrome
b mutations have been described as causing exercise in-
tolerance, proximal limb weakness, and elevated lactate
levels (Andreu et al. 1999; Legros et al. 2001). More-
severe multisystem manifestations, including symptoms
in the CNS, have also been reported (Keightley et al.
2000; Wibrand et al. 2001). So far, no mutations have
been reported in the nuclear-encoded subunits of complex
III.
The Bcs1p protein, the Saccharomyces cerevisiae hom-
olog for human BCS1L (BCS1-like), is an assembly factor
of complex III. It is a mitochondrial inner-membrane pro-
tein with a single transmembrane domain. A short N-
terminus is located in the mitochondrial intermembrane
space, and the bulk of the protein lies in the matrix. It
belongs to the conserved AAA protein family (ATPases
associated with various cellular activities) and acts as a
chaperone necessary for the assembly of Rieske FeS and
Qcr10p subunits into complex III (Nobrega et al. 1992;
Fo¨lsch et al. 1996; Cruciat et al. 1999). The human
BCS1LmRNA sequence has been identified by searching
the EST database with the yeast Bcs1p protein sequence,
and it has been proven that human BCS1L is a mito-
chondrial inner-membrane protein, like yeast Bcs1p (Pe-
truzzella et al. 1998). Here we report that a missense
mutation in BCS1L results in GRACILE syndrome and
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Table 1
Clinical Characteristics of the Finnish Patients with GRACILE Syndrome, Compared with Three British Infants with Different BSC1L
Mutations
CLINICAL CHARACTERISTIC
NORMAL
RANGE
PATIENTS WITH GRACILE SYNDROMEa BRITISH PATIENTSb
n Median IQ25 IQ75 Patient 1 Patient 2 Patient 3
Male/female 5/12 M F F
Gestational age (wk) 17 37.6 35.3 38.4 38 39 38
Birth weight (g) 17 1,560 1,310 1,790 2,020 1,830 1,840
Birth weight (SD score) 17 4.0 4.2 3.6 3.3 3.8 3.5
Birth length (cm) 17 43 40 45 47 45 48
Head circumference (cm) 17 31 30 32 31 31 31
1-min Apgar score 17 8 7 9 9 ND ND
Umbilical arterial pH 17.20 17 7.30 7.26 7.30 ND ND ND
pH at admission to intensive care 7.35 to 7.43 17 7.00 6.95 7.09 7.13 7.09 7.09
Base excess (mmol/liter) 2.5 to 2.5 17 21 25 20 20 20 13
Blood lactate (mmol/liter) .7 to 1.8 17 11.8 6.5 19.9 23.5 10.9 13.8
Blood pyruvate (mmol/liter) .04 to .07 17 .12 .08 .16 .31 .27 .33
Lactate:pyruvate ratio !25 17 81 52 130 76 40 42
Age at death (d) 17 7 2 68 2 42 105
Aminoaciduria 17 All Yes Yes Yes
Cholestasis 17 All No Yes Yes
Neurological symptoms:
Hypotonia 17 None Yes Yes Yes
Seizures 17 None Yes No No
Iron metabolism:
Serum ferritin (mg/liter) !150 6 1,314 1,193 2,148 ND ND ND
Serum iron (mmol/liter) 19 to 48 6 14.0 11.6 16.4 ND ND ND
Serum transferrin (g/liter) 1.1 to 1.8 5 .72 .72 .76 ND ND ND
Transferrin saturation (%) 30 to 60 5 81 61 91 ND ND ND
Hemosiderosis of liver (score 0–4) 0 13 3 1 4 ND ND ND
Liver iron content (mg/mg dry weight) 990 to 2,800 5 5,470 3,990 5,700 ND ND ND
a IQ p interquartile range.
b ND p not determined. British patients 1–3 have been described by Morris et al. (1995).
provide data suggesting a new role for BCS1L in human
iron metabolism.
Subjects and Methods
Study Subjects
DNA samples from 17 Finnish patients with GRAC-
ILE syndrome, 22 parents, 13 siblings, and 3 half-sib-
lings, from 11 families, as well as DNA from 3 British
infants, were used for sequence analyses in the present
study. The symptoms in the British patients (Morris et
al. 1995) resembled those of the Finnish patients with
GRACILE syndrome, but there were some remarkable
differences (table 1). The British infants had complex III
deficiency, whereas, in the Finnish patients, complex III
activity did not seem to be affected (Fellman et al. 1998).
Moreover, the British patients had neurological symp-
toms, whereas the Finnish patients with GRACILE syn-
drome had no neurological or neuropathological ab-
normalities. We included 494 Finnish individuals as
control individuals in mutation screening, 70%ofwhom
originated from eastern and central Finland, where the
ancestors of the affected infants had lived (Fellman et
al. 1998); we also used a control panel of 50 white
individuals (HD50CAU; Coriell Cell Repositories). This
control panel consisted of 50 Americans with ancestry
in different parts of Europe. Autopsy samples, muscle
biopsy specimens, or fibroblast cell lines of nine Finnish
patients with GRACILE syndrome were used for RNA
extraction and mitochondrial enzyme–complex mea-
surements. This study has been approved by the ethical
committee of the Hospital for Children and Adolescents,
Helsinki University Central Hospital, Finland, and pa-
rental informed consent was obtained.
Determining the Localization and Structure
of the BCS1L Gene
BCS1L has been localized to the critical GRACILE re-
gion (Visapa¨a¨ et al. 1998) in both the NCBI MapViewer
(Human Genome at NCBI Web site) and the UCSC Hu-
man Genome Project Working Draft (UCSC Genome
Bioinformatics Web site). Localization of BCS1L was al-
so confirmed by radiation hybrid (RH) mapping using
Stanford medium-resolution RH panel G3 (Research
Genetics).
Both the mRNA sequence and the genomic structure
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of the BCS1L gene have been published elsewhere (Pe-
truzzella et al. 1998; de Lonlay et al. 2001). However,
the genomic sequence published by de Lonlay et al. (2001)
was partially incomplete for the noncoding part of the
first exons, which we determined using biocomputing
tools. The genomic clone (RP11 1077K22) containing
BCS1L was identified by a BLAST search with BCS1L
mRNA sequence. Because we had noticed variations in
the 5′ UTRs in the various BCS1L mRNA sequences, we
searched the human EST database and the nucleotide se-
quence database with only the coding part of the BCS1L
mRNA sequence, using the BLASTN algorithm at the
NCBI BLAST service, in order to find all the different
splice variants of this gene. The EST and mRNA se-
quences were aligned with the genomic clone through use
of the Sequencher computer program and were divided
into exons so that all the exon-intron boundaries followed
the GT-AG rule (Mount 1982).
Sequencing and Mutation Screening of the BCS1L
Gene
Sequencing was performed using a BigDye terminator
kit and ABI 377 and ABI 3700 automated sequencers
(Applied Biosystems). The genomic clone RP11 1077K22
was used for primer planning. ThewholeBCS1L genomic
sequence was amplified by PCR from the DNA samples
from two Finnish patients with GRACILE syndrome,
three British patients with similar symptoms (Morris et
al. 1995), and two control individuals, in 13 overlapping
pieces, and was sequenced using the same primers. The
sequence covered 5.5 kb, starting 2,020 bp upstream from
the start codon and ending 1,040 bp downstream from
the stop codon of BCS1L.
The coding region of BCS1L was also sequenced us-
ing RT-PCR products. For RT-PCR sequencing, total
RNA was extracted from the liver tissue of one patient
with GRACILE syndrome and two control individuals,
through use of the RNeasy Mini Kit (Qiagen). The
GenBank AF038195 mRNA sequence was used as a
reference.
Screening for the 232ArG (S78G) point mutation in
the Finnish patients with GRACILE syndrome and their
parents was performed by direct sequencing (ABI;Applied
Biosystems). Mutation screening in siblings and control
samples was performed using solid-phase minisequencing
(Syva¨nen et al. 1993). The PCR primer sequences for
minisequencing were CTATGCCTGGTTGCTTAGCTG
(5′ end biotinylated) and CTTCGTTCTACCCGAATCC-
ATT, and the detection primer sequence was AAGGTAC-
GAAGTCTCGACAC. For other mutations, the control
individuals were screened by direct sequencing.
Northern Blot Analysis
Messenger RNAs for northern blot analysis were ex-
tracted from two GRACILE and one control fibroblast
cell line, as well as from the liver tissue of one patient
with GRACILE syndrome and one control individual,
through use of the Oligotex mRNADirectMini kit (Qia-
gen). The control liver tissue was derived from an adult
who died in an accident, and the control fibroblast cell
line was also adult-derived. Northern blotting to Hy-
bond-XL nylon membrane (Amersham Pharmacia Bio-
tech) was performed using standard procedures. A 493-
bp probe was produced by RT-PCR using the primers
TTCTGGCTCTGAAGGACAATCC and GCTGTGTA-
CATCACGGTCTTCC and was labeled with 32P, using
a random primer DNA labeling system (Life Technol-
ogies). Hybridizations were performed in Expresshyb
hybridization solution (Clontech), as suggested by the
manufacturer.
Expression Plasmid Construction, Cell Culture,
and Transfections
BCS1L cDNA was PCR-cloned to a pGEM-T Easy
vector (Promega), through use of linker primers intro-
ducing the FLAG sequence immediately before the stop
codon. IMAGE clone 44576 was used as a template in
the PCR. The 232ArG mutagenesis, resulting in an
S78G amino acid change, was performed in pGEM-T
Easy vector, through use of the QuickChange site-di-
rected mutagenesis kit, according to the manufacturer’s
instructions (Stratagene). Wild-type and mutant BCS1L
cDNAs with a C-terminal FLAG tag were then sub-
cloned to pCMV5 expression vector (Andersson et al.
1989). The constructs were confirmed by sequencing.
COS-1 cells were obtained from the American Type
Culture Collection and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Cellgro), supple-
mented with 10% fetal bovine serum (FBS; Cellgro) and
antibiotics (Life Technologies) in 5% CO2 at 37C. One
hundred thousand cells per well were plated in six-well
plates 1 d prior to transfection. Cells were transiently
transfected using Lipofectamine and PLUS reagent (Life
Technologies), following the manufacturer’s guidelines.
Immunofluorescence Microscopy
For immunofluorescence microscopy, COS-1 cells
were plated on cover slips and were transfected as de-
scribed above. Forty-eight hours after transfection, cells
were incubated in DMEM without FBS, in the presence
of 50 mg/ml of cycloheximide (Sigma) to halt protein
synthesis, for 1 h, and then for an additional 30 min
with cycloheximide and 200 nM MitoTracker Red
CMXRos (Molecular Probes), for mitochondrial stain-
ing. Thereafter, the cells were fixed with methanol, were
blocked with 0.5% BSA/0.2% saponin (Sigma), and
were incubated with anti-FLAG M2 antibody (Strata-
gene; 1/500 dilution). The cells were washed with 0.5%
BSA/0.2% saponin and were stained with fluorescein
isothiocyanate (FITC)–conjugated anti-mouse second-
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ary antibody (Sigma; 1/200 dilution). After washingwith
PBS, the cells were mounted in glycerol and were viewed
with a Leica DMR immunofluorescence microscope
(Leica Microscope and Scientific Instruments Group),
using a Quips FISH image capture system (Applied Im-
aging Corporation).
Western Blot Analysis
For western blot analysis, COS-1 cells were lysed 48
h after transfection with lysis buffer (50 mM Tris [pH
8.0], 150 mM NaCl, 1% (octylphenoxy)polyethoxyeth-
anol, 0.5% deoxycholic acid, 0.1% SDS) supplemented
with protease inhibitors (Complete; Roche Diagnostics),
via incubation at 4C for 20 min with shaking, followed
by centrifugation and retention of the supernatant. Sam-
ples were denatured at 60C for 5 min and were elec-
trophoresed on a 10% SDS-PAGE gel with a Low Range
protein marker (BioRad). Western blotting was per-
formed according to standard procedures, using the Hy-
bond-P membrane (Amersham Pharmacia Biotech). The
membrane was stained with anti-FLAG M2 antibody
(Stratagene; 1/1,000 dilution), the secondary antibody
being peroxidase-conjugated anti-mouse IgG (Sigma; 1/
10,000 dilution). The signals were detected using ECL
western-blotting detection reagents (Amersham Phar-
macia Biotech).
Pulse-Chase Analysis
The half-lives of thewild-type and S78Gmutant BCS1L
polypeptides were determined by pulse-chase experi-
ments. Cells were metabolically labeled 36 h after trans-
fection, by starving them in methionine- and cysteine-free
medium (Life Technologies) for 1 h and thereafter labeling
themwith 50 mCi/ml of both [35S]methionine and [35S]cys-
teine (Amersham Pharmacia Biotech) for 1 h. The cells
were then incubated for 0, 12, 24, 36, or 48 h, in chase
media (DMEM, 2% FBS, and antibiotics), and were lysed
with lysis buffer, as described above. The lysed cells were
immunoprecipitated with anti-FLAGM2 antibody (Strat-
agene; 1/1,000 dilution) and Protein A/G Sepharose
(Santa Cruz Biotechnology). Immunocomplexeswere sep-
arated on 10% SDS-PAGE and were visualized by fluo-
rography, using Amplify reagent (Amersham Pharmacia
Biotech). The results were analyzed by densitometry.
Yeast Complementation Studies
Human BCS1L cDNA was PCR-cloned to pBluescript
(Stratagene) vector, using linker primers. IMAGE clone
44576 served as a template. Four hundred eighty base
pairs of yeast BCS1 upstream sequence and 210 bp of
yeast BCS1 downstream sequence were amplified by PCR
from yeast genomic DNA and were cloned to the p-
Bluescript plasmid containing the human BCS1L cDNA.
The 232ArG mutagenesis in BCS1L cDNA, resulting in
an S78G amino acid change, was performed using the
QuickChange site-directed mutagenesis kit, according to
the manufacturer’s protocol (Stratagene). The whole cas-
sette, containing yeast BCS1 promoter, human BCS1L
cDNA, and yeast BCS1 terminator, was then subcloned
to the high-copy yeast expression vector pRS425 (Sikorski
and Hieter 1989).
The yeast BCS1 gene was PCR-cloned, as one frag-
ment containing a 480-bp upstream sequence, the coding
region, and a 210-bp downstream sequence, to a pGEM-
T Easy vector (Promega), using yeast genomic DNA as
a template in PCR. The 343,344TCrGG mutagenesis,
resulting in a S115G amino acid change (corresponding
to S78G in human), was performed with a QuickChange
site-directed mutagenesis kit. The gene was subcloned
both to the high-copy yeast expression vector pRS425
and to the low-copy vector pRS315 (Sikorski and Hieter
1989). All constructs were confirmed by sequencing.
Yeast strain Y14211 (EUROSCARF, European S. cer-
evisiae archives for functional analysis), deleted forBCS1,
was transformed with the yeast expression constructs de-
scribed above. Transformations were performed by the
lithium acetate procedure (Ito et al. 1983). Individual
transformants were purified and checked for growth on
YPEG plates (3% glycerol, 2% ethanol, 2% peptone, 1%
yeast extract, and 2% agar). To control the growth on
glucose, the same transformants were also streaked on
YPD plates (2% glucose, 2% peptone, 1% yeast extract,
and 2% agar) and on synthetic dextrose (SD) minimal
medium plates without leucine (2% glucose; 0.67% yeast
nitrogen base; 2% agar; 20 mg/ml histidine, uracil, and
tryptophan; and 30mg/ml adenine and lysine).
Activity Measurements of Mitochondrial Enzyme
Complexes
Mitochondria were isolated from muscle biopsy spec-
imens of five patients with GRACILE syndrome and
from several autopsy-derived tissues obtained from four
patients 2–7 h postmortem. Age-matched control sam-
ples from patients without any mitochondrial diseases
were available for muscle biopsy specimens and myo-
cardial autopsy samples. The activities of respiratory
chain enzymes (NADH:cytochrome c oxidoreductase
[complex I  III], succinate:cytochrome c oxidoreduc-
tase [complex II  III], succinate:ubiquinone oxidore-
ductase [complex II], and cytochrome c oxidase [com-
plex IV]) were measured spectrophotometrically (Ma-
jander et al. 1995). A modified spectrophotometrical as-
say (Rustin et al. 1994), including separate assessment
of NADH:ubiquinone oxidoreductase (complex I) and
ubiquinol:ferricytochrome-c oxidoreductase (complex
III), was used to measure the enzyme activities from three
deep-frozen liver samples and one muscle sample of the
patients. The control tissues for these measurements
were from children and adults who had died of unrelated
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Table 2
BCS1L Mutations Detected in the Finnish Patients with GRACILE Syndrome and in Three British Patients
PATIENT AND MUTATION TYPE
HOMOZYGOUS/
HETEROZYGOUS LOCATION
NUCLEOTIDE
CHANGE
PREDICTED
CONSEQUENCE
Genomic
DNAa cDNA
Finnish patients with GRACILE syndrome:
Missense Homozygous Exon 2 232ArG 232ArG S78G
British patient 1:
Nonsense Heterozygous Exon 2 166CrT 166CrT R56STOP
Missense Heterozygous Exon 7 1986TrC 980TrC V327A
British patient 2:
Pathogenicity not confirmed Heterozygous Intron 1 588TrA … ?
Splice site Heterozygous Intron 2, donor 321GrT … Polypeptide truncation
British patient 3:
Missense Heterozygous Exon 2 232ArG 232ArG S78G
Missense Heterozygous Exon 3 529GrA 431GrA R144Q
NOTE.—Other nucleotide changes observed both in patients and control individuals include376CrT in intron 1, which is a previously
unknown SNP, and 1295TrC in intron 5, which is a known SNP in the NCBI database (rs#2303561).
a Nucleotide 1 is nucleotide 2021 in the BCS1L genomic sequence (GenBank accession number AF516670).
disorders; the tissues had been stored at 80C. In ad-
dition, respiratory chain enzyme activities were mea-
sured from the fibroblasts of two patients with GRAC-
ILE syndrome, as described elsewhere (Pitka¨nen and
Robinson 1996).
Results
Localization and Structure of the BCS1L Gene
We first confirmed the localization of BCS1L to the
critical 1.4-Mb GRACILE region by comparing the RH
panel data of BCS1L with the RH data of the genetic
markers constituting the shared founder haplotype in
GRACILE chromosomes. The hybrid clones positive for
BCS1L were exactly the same as those positive for the
markers D2S2250 and D2S433, which demonstrated the
strongest linkage disequilibrium in GRACILE chromo-
somes (Visapa¨a¨ et al. 1998), indicating that BCS1L is
located in the immediate vicinity of these markers (fig.
1A).
Comparison of the different EST andmRNA sequences
suggested that the 5′ end of the BCS1L transcript can be
alternatively spliced. Fifteen EST or mRNA sequences
found in public databases and Celera (GenBank accession
numbers and Celera sequence numbers for the EST and
mRNA sequences are provided in the Electronic-Database
Information section of this article) represented six differ-
ent splice variants. Two of the variants (GenBank acces-
sion numbers AF026849 and AF038195) were repre-
sented several times and had been found in clones
originating from normal tissues, whereas the other four
were rare and were reported only in EST libraries of can-
cer tissues or had a nonspecified tissue origin in the da-
tabases. Inmost transcripts, the first exon is small (20–120
bp), and the size of the first intron varies from 800 to
1,200 bp. The second exon is 369 bp, starts 49 bp before
the start codon, and contains an in-frame stop codon 42
bp upstream from the start codon. This exon and all six
exons thereafter are identical in all splice variants (fig.
1B). A few clones contained an additional short exon in
the middle of the first intron. The exons span 3.4–3.8 kb
in the genomic sequence, and the size of the spliced tran-
script varies from 1.4 kb to 1.5 kb. The coding region is
1,260 bp, encoding a polypeptide of 419 amino acids
(Petruzzella et al. 1998).
Sequence Analysis of the BCS1L Gene
Table 2 and figure 1B summarize the results of the
sequence analysis. All Finnish patients with GRACILE
syndrome were homozygous for a 232ArG mutation in
the second exon of BCS1L, which causes an S78G amino
acid change. All parents were heterozygous for this mu-
tation, and the siblings and half-siblings of the patients
were either homozygous for the normal allele or hetero-
zygous. The two sequenced Finnish patients with GRAC-
ILE syndrome had no other nucleotide changes in the
BCS1L genomic sequence (GenBank accession number
AF516670). The coding region of BCS1L was also se-
quenced from the RT-PCR product from the liver RNA
of one Finnish patient and two control individuals. Nei-
ther defective splicing nor any nucleotide changes other
than the 232ArG mutation were detected in the patient.
Of the 494 Finnish control individuals and 50 otherwhite
individuals screened for the S78G mutation, 1 Finnish
control individual was a heterozygous carrier of this mu-
tation, and all other control individuals were homozygous
for the normal allele.
Sequencing ofBCS1L in the three British patients (Mor-
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Figure 2 Northern blot analysis of BCS1L in Finnish patients
with GRACILE syndrome. For the fibroblast filter, each linewas loaded
with 9 mg poly-A-RNA; for the liver filter, each line was loaded with
6 mg poly-A-RNA. The same filters were rehybridized with b-actin
cDNA, to control for the total mRNA quantity.
ris et al. 1995) revealed three missense mutations, one
premature stop codon, one splice-site mutation, and one
intronic nucleotide change. Patient 1 was a compound
heterozygote for a premature stop codon at amino acid
position 56 in the second exon, as well as for a V327A
missense mutation in the seventh exon. Patient 2 had a
heterozygous splice-donor mutation changing the first G
of the second intron to a T, as well as a TrAheterozygous
single-nucleotide change in the middle of the first intron,
588 bp upstream from the start codon of the BCS1L.
Patient 3 was a compound heterozygote for two missense
mutations: the Finnish S78G mutation in exon 2 and an
R144Q mutation in exon 3. None of these mutations,
including the intronic TrA change of patient 2,was found
in 140 control individuals, 90 of whom were Finnish and
50 of whomwere of other white ancestry. Two SNPswere
observed both in the British infants and in two sequenced
control individuals (table 2).
Northern Blot Analysis of Patients with GRACILE
Syndrome
Northern blot analysis of BCS1L was performed in
the Finnish patients with GRACILE syndrome, to mon-
itor the steady-state expression level of the gene and
possible differences in the size of the transcript. An ∼1.4-
kb transcript was detected in both patient and control
fibroblasts, as well as in patient and control liver (fig.
2). There was no obvious difference in the steady-state
expression level between patients and control individ-
uals. Another faint signal of ∼2.7 kb was observed in
both patients and control individuals.
Effect of the S78G Mutation on the Expression,
Targeting, and Stability of BCS1L Protein in Transiently
Transfected COS-1 Cells
It has previously been shown that human BCS1L pro-
tein is targeted unmodified to the inner mitochondrial
membrane in vitro (Petruzzella et al. 1998). To study
the effect of the S78G mutation on the synthesis, tar-
geting, and stability of the BCS1L protein, we subcloned
the coding region of both wild-type and mutant cDNA
into pCMV5 expression vector with a C-terminal FLAG
tag. Intracellular targeting of the wild-type and mutant
BCS1L polypeptides was studied in the transiently trans-
fected COS-1 cells, by immunofluorescence microscopy.
The staining with the anti-FLAG antibody completely
overlapped with the mitochondrial staining, both in the
cells transfected with the wild-type construct and in the
cells transfected with the mutant construct (fig. 3), in-
dicating that the S78G mutation does not influence the
mitochondrial targeting of the BCS1L protein in vitro.
Western blotting of the transiently transfected cell ly-
sates revealed a single ∼46-kD polypeptide. There was
no obvious difference in size or intensity between the
signal from the wild-type and mutant polypeptides (fig.
4), suggesting that the S78G mutation does not affect
the synthesis or posttranslational modifications of the
BCS1L polypeptide. Pulse-chase experiments were per-
formed to monitor the stability of the mutant BCS1L
protein. The half-life of the FLAG-tagged wild-type
BCS1L polypeptide was 41 h, whereas that of the S78G
mutant was only 14 h, suggesting that the S78G mu-
tation decreases the stability of the BCS1L polypeptide
in vitro (fig. 5).
Yeast Complementation Studies
Yeast BCS1p protein has been shown to be essential
for the assembly of the mitochondrial respiratory chain
complex III (Nobrega et al. 1992; Cruciat et al. 1999).
Yeast strains deleted for the BCS1 gene cannot grow on
glycerol, since, on nonfermentable carbon sources, yeast
cells are dependent on oxidative respiration. On glucose,
BCS1-deletion strains are able to grow by utilizing an-
aerobic metabolism. Human BCS1L protein is highly
homologous to yeast BCS1p protein (50% identity), and
human BCS1L can partially rescue a yeast strain deleted
for BCS1 (de Lonlay et al. 2001). This facilitated the
use of yeast complementation studies in monitoring the
functional effect of the S78G mutation.
We tested the effect of the S78G mutation on the abil-
ity of human BCS1L to restore oxidative respiration in
a BCS1 deletion strain. The BCS1-deletion yeast strain
Y14211 was transformed with the wild-type and
232ArG (S78G) mutant BCS1L cDNAs in a high-copy
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Figure 3 Subcellular localization of the wild-type and S78G mutant BCS1L polypeptides in transiently transfected COS-1 cells. The BCS1L
polypeptides were detected with anti-FLAG antibody (green), and the distribution was comparedwithmitochondrial staining (red).Colocalization
is indicated in yellow. Magnification p 630#.
yeast expression plasmid, pRS425. As a positive control,
we also transformed the same strain with the wild-type
yeast BCS1 cDNA in the same vector, and we used the
plain vector as a negative control. The purified transfor-
mants were streaked on YPEG (ethanol-glycerol), YPD,
and SD plates without leucine (vector selection) and were
incubated at 30C and 37C. On YPD and SD-leu plates,
all the transformants grew equally well at both temper-
atures, indicating that all the transformants were viable
on glucose. On YPEG plates, the yeast BCS1 transfor-
mants were clearly growing after 48 h incubation. The
wild-type human BCS1L transformants grew, but con-
siderably more slowly, showing the first signs of growth
after 4 d at 37C and after 6 d at 30C. The S78G mutant
and the vector-only transformants did not show any
growth, even after incubation for 2 wk, suggesting that
the S78G mutation causes a functional defect in the
BCS1L protein (fig. 6).
We also introduced a S115G mutation (corresponding
to the S78G mutation in human) into the yeast BCS1
gene and transformed the Y14211 yeast strain with the
wild-type and S115G mutant yeast BCS1 gene in the
low-copy yeast expression vector pRS315. The mutant
transformants grew on YPEG plates as well as the wild-
type transformants did, indicating that the S115G amino
acid change does not cause any significant defect in the
yeast BCS1p protein.
Complex III Enzyme Activity Measurements
The decreased complex III activities (37% of control
values in patient 1 and 15% of control values in patients
2 and 3) in the skeletal muscle of the British patients
have been described elsewhere in detail (Birch-Machin
et al. 1989; Morris et al. 1995). The Finnish patients
with GRACILE syndrome have had normal complex III
activities in isolated mitochondria of all tissues studied
(Fellman et al. 1998), but, because of an evident dis-
crepancy between the English and Finnish findings, we
confirmed the findings in detail.
All the respiratory chain enzyme activities measured
in isolated mitochondria from skeletal muscle biopsies
of the Finnish patients were within the normal range
(table 3). From their autopsy-derived tissues, the myo-
cardial samples showed activities higher than in the au-
topsy controls (table 4). However, the complex III–
dependent activities were relatively less increased than
the complex IV activity. Activities similar to those in the
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Figure 4 Expression of the wild-type and S78G mutant BCS1L
polypeptides. COS-1 cells transfected with the wild-type and mutant
BCS1L constructs were subjected to western blot analysis using anti-
FLAG antibody. Each lane was loaded with 25 mg protein. pCMV5p
cells transfected with the vector only.
Figure 5 Stability of the wild-type and S78G mutant BCS1L
polypeptides. Transiently transfected COS-1 cells were pulse-labeled
for 1 h and were chased for 0, 12, 24, 36, and 48 h. The BCS1L
polypeptides were immunoprecipitated, were separated on 10% SDS-
PAGE, and were visualized by fluorography. The radioactive bands
were quantitated by densitometry. The results are presented as a per-
centage of values at 0 h chase. The values on the curve are average
values of duplicate experiments, with error bars showing the SD.
myocardium were found in liver, brain, and kidney spec-
imens, for which sufficient controls were not available.
Since these activities represent the values of indirectmea-
surements of complex III, deduced from the combined
activities with complex I and complex II, we also as-
sessed complex III separately in homogenized tissue sam-
ples. In two deep-frozen (70C) liver tissue samples,
all the mitochondrial enzyme activities were low, indi-
cating a tissue preservation problem. However, in liver
and muscle homogenates of one patient (specimens
stored in liquid nitrogen), the activities were generally
within the normal range (table 5). The liver showed nor-
mal complex III activity, whereas in the muscle complex
III activity was moderately decreased. In proportion to
citrate synthase (CS) activity, the complex III activity of
the muscle specimen was reduced by 1.5 SD, compared
with the controls. In addition, no deficiencies in respi-
ratory chain enzyme activities (complexes I  III, II 
III, and IV) were detected in fibroblast cell lines of pa-
tients with GRACILE syndrome.
Discussion
Our results strongly suggest that GRACILE syndrome
in the Finnish patients is caused by an S78G amino acid
change in the BCS1L protein. The protein has previously
been characterized as an essential factor for the assembly
of respiratory chain complex III. We show here that,
surprisingly, the S78G mutation does not seem to affect
complex III activity considerably, but the patients have
iron overload. This finding suggests a completely new
and unexplored function for BCS1L in cellular iron
metabolism.
We found the same BCS1L mutation in all Finnish
patients with GRACILE syndrome, as well as five mu-
tations (including the Finnish mutation) in three British
patients with similar symptoms. The clinical character-
istics of both the Finnish and British patients included
severe fetal growth retardation, lactic acidosis, amino-
aciduria, and death before the age of 5 mo. The Finnish
patients with GRACILE syndrome did not have any
neurological problems or clearly decreased complex III
activity, in contrast to the British patients, but the Finn-
ish patients had marked hepatic iron overload, associ-
ated with abnormal levels of proteins involved in iron
transfer and storage, and free plasma iron. Four differ-
ent mutations in BCS1L have also been identified else-
where, in five patients from four unrelated Turkish fam-
ilies (de Lonlay et al. 2001). The symptoms in these
patients varied, the essential findings being metabolic
acidosis, tubulopathy, hepatic features, and severe neu-
rological problems. Growth retardation was less severe
than in the Finnish and British patients. Three of the
patients died at the age of 3 mo to 2 years, one was 9
years old, and one was lost to follow-up at the age of
5 mo. Like the British infants, all the Turkish patients
had complex III deficiency. Unfortunately, iron metab-
olism was not studied in either the British or the Turkish
patients.
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Figure 6 Yeast complementation experiment with BCS1L. The BCS1 deletion yeast strain was transformed with the wild-type and mutant
BCS1L constructs in a high-copy yeast expression plasmid pRS425. The wild-type yeast BCS1 cDNA in the same vector was used as a positive
control, and the plain vector was used as a negative control. A, YPEG (ethanol-glycerol) plate incubated at 30C for 11 d. B, YPEG plate
incubated at 37C for 8 d. C, YPD (glucose) plate incubated at 30C for 3 d.
The S78G mutation segregated without exception
with the disease phenotype in the Finnish families with
GRACILE syndrome, and only one carrier was detected
in 544 control individuals, which supports the patho-
genic role of the mutation. The causative role was fur-
ther supported by the finding of the same mutation, in
heterozygous form, in a British patient, who also had
a R144Q mutation in her other allele. In other British
patients, we identified an early stop mutation, a splice-
site mutation, and a V327A missense mutation. S78 is
highly conserved across the species, and the predicted
effect of the serine-to-glycine change on the polypeptide
is considerable. The smallest amino acid, glycine enables
the polypeptide backbone to make turns that are not
possible with any other residue, and it also lacks the
hydroxyl group and the polarity of serine. Our in vitro
experiments in COS-1 cells suggest that the S78G mu-
tation does not affect targeting or posttranslational
modifications of the BCS1L protein but results in de-
creased stability of the protein. The functional signifi-
cance of most other mutations is also obvious: the pre-
mature stop codon is a truncating mutation and can be
considered pathogenic even without functional evi-
dence. The R144Q mutation changes a basic and
charged arginine into acidic and uncharged glutamine.
R144 is conserved in mouse, and, in both Drosophila
melanogaster and S. cerevisiae, it is replaced by lysine,
another basic and charged amino acid, being relatively
well conserved. The V327A change appears to be the
least dramatic of the current mutations, since both val-
ine and alanine are small, nonpolar amino acids without
functional groups. V327 is not strictly conserved either,
since in S. cerevisiae it is replaced by threonine, a polar
amino acid. However, since this mutation was not found
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Table 3
Respiratory Chain Enzyme Activity in Muscle Biopsy Samples from Finnish Patients with GRACILE Syndrome
SAMPLEa
ACTIVITY (RATIO TO CS)b
(nmol/min/mg mitochondrial protein)
Complex I  III Complex II  III Complex II Complex IV CS
Patient B 65 (.13) 89 (.18) 188 (.37) 1,169 (2.31) 506
Patient C 76 (.11) 154 (.23) 195 (.29) 3,093 (4.54) 682
Patient D 84 81 249 1,815 NDc
Patient E 132 (.21) 163 (.26) 101 (.16) 1,929 (3.08) 626
Patient F 218 (.27) 61 (.07) 154 (.19) 2,219 (2.72) 816
Control ( )dnp 7 140  70 (.14) 197  88 (.20) 162  51 (.17) 2,521  759 (2.60) 969  243
a Samples are isolated mitochondria from muscle biopsy specimens.
b Activity measurement performed as described by Majander et al. (1995).
c ND p not determined.
d Data are mean  SD (ratio to CS calculated from controls’ mean).
Table 4
Respiratory Chain Enzyme Activity in Autopsy Samples of
Myocardium from Finnish Patients with GRACILE Syndrome
SAMPLEa
ACTIVITYb
(nmol/min/mg mitochondrial protein)
Complex IIII/
Complex II
Complex IIIII/
Complex II
Complex IV/
Complex II
Patient C 2.9 2.1 28
Patient D .4 .6 4.7
Patient E 1.4 1.4 32
Patient F .6 .2 19
Control ( )cnp 5 1.1  .4 1.6  .7 8.8  2.6
a Samples are isolated mitochondria from autopsy samples obtained
2–7 h after death.
b Activity measurements performed as described by Majander et al.
(1995).
c Data are mean  SD.
in 140 control individuals and since the early stop mu-
tation found in the other allele of the same patient is
an obligatory mutation, we consider this V327A sub-
stitution to be a likely mutation as well. It is located in
the conserved ATP-binding AAA-sequence motif of the
BCS1L polypeptide, which could explain the pathoge-
nicity of this relatively moderate amino acid change (fig.
1B and 1C).
In British patient 2, we identified a heterozygous
splice-donor mutation and a heterozygous TrA nucle-
otide change in the middle of the first intron. The path-
ogenicity of these nucleotide changes has not yet been
proven at the RNA level. However, since the phenotype
of patient 2 was identical to that of patient 3, we con-
sider BCS1L mutations to be a likely cause underlying
the symptoms of patient 2 as well. Since the splice-site
mutation abolishes a classical splice-donor consensus
sequence, it is likely to result in truncation of the pro-
tein. The importance of the nucleotide change in the
first intron is more questionable. It was not present in
140 control individuals, implying that it does not rep-
resent a common SNP. However, the 20 bp surrounding
the nucleotide variant are not conserved in mouse (Cel-
era mouse sequence GA_x5J8B7W5GLS), so the func-
tional importance of the region is not supported by
phylogenetic conservation. We did not identify any
other possible mutations in the DNA of patient 2, but
we cannot exclude the possibility of a regulatory mu-
tation located far upstream.
The carrier frequency of the S78G mutation observed
among the Finnish control individuals was lower than
expected. The incidence of GRACILE syndrome is 1/
47,000 in Finland, predicting a carrier frequency of ∼1/
110. The ancestors of the families with GRACILE syn-
drome originated from rural areas in eastern and central
Finland (Fellman et al. 1998), and most of the families
still live in these regions. Therefore, the carrier fre-
quency in eastern and central Finland is estimated to be
higher, ∼1/80, whereas in western Finland it is predicted
to be very low. Thus, we should have identified about
five carriers among our 494 control individuals, 70%
of whom originated from the eastern and central parts
of Finland. The GRACILE mutation most probably rep-
resents a relatively new mutation, enriched in the re-
stricted regional subisolates of eastern and central Fin-
land. We have earlier demonstrated quite significant
regional differences in our DNA array-based identifi-
cation of the carriers of Finnish mutations, reflecting
the effect of multiple population bottlenecks during the
inhabitation of the country (Pastinen et al. 2001).
The sequence information ofBCS1L in databases sug-
gests alternative splicing of BCS1LmRNA. These splice
variants would not affect the structure of the translated
BCS1L polypeptide, since the second exon containing
the start codon and all six exons thereafter are identical
in all splice variants. It is also unlikely that the alter-
native 5′ UTRs would affect the translation initiation,
because an in-frame stop codon lies 42 bp before the
start codon, making an earlier translation initiation im-
possible. The use of a methionine further downstream
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Table 5
Respiratory Chain Enzyme Activity in Autopsy Samples of Liver and Muscle from a Finnish Patient with GRACILE Syndrome
SAMPLEa
ACTIVITY (RATIO TO CS)b
(nmol/min/mg mitochondrial protein)
Complex I Complex II Complex II  III Complex III Complex IV CS
Liver:
Patient C 11 (.12) 67 (.74) 15 (.17) 25 (.28) 5.5 (.06) 90
Control ( )cnp 13 19 [8–37] (.23) 110 [58–160] (1.33) 28 [13–42] (.34) 36 [14–68] (.43) 46 [26–70] (.55) 83 [41–117]
Muscle:
Patient C 32 (.11) 54 (.19) 47 (.16) 28 (.10) 147 (.52) 285
Control ( )cnp 30 26 [13–44] (.12) 47 [23–86] (.22) 43 [20–75] (.20) 57 [21–118] (.27) 126 [75–205] (.59) 214 [140–334]
a Samples are from tissue stored in liquid nitrogen.
b Activity measurements of tissue homogenates performed as described by Rustin et al. (1994).
c Data are mean [5%–95% range] (ratio to CS calculated from controls’ mean).
as an alternative start codon is not likely either, since
the next methionine is residue 48, which is located
downstream from the only transmembrane domain of
the protein. Alternative splicing of the 5′ UTR could,
however, enable tissue-specific up- or downregulation
of BCS1L expression. The occurrence of various splice
variants in different tissue and cell types and their im-
portance for the regulation of gene expression remains
to be verified by experimental tools.
The only known function of BCS1L protein is the chap-
erone function in the assembly of complex III in the res-
piratory chain. This has been studied in detail in yeast
(Nobrega et al. 1992; Cruciat et al. 1999), in which the
BCS1p protein has been shown to act as an ATP-depen-
dent chaperone maintaining the precomplex in a com-
petent state for the assembly of Rieske FeS and Qcr10p
proteins. In human, BCS1L has a related function, since
both our British patients and the Turkish patients with
BCS1Lmutations (de Lonlay et al. 2001), unequivocally
had a complex III defect. However, in the Finnish patients
with GRACILE syndrome, complex III activity was not
severely affected. This would suggest that the Finnish
S78G mutation disturbs an unknown BCS1L function
that does not involve the assembly of complex III but
probably has a role in iron metabolism. Interestingly, the
Finnish patients with GRACILE syndrome did not have
any neurological problems, in contrast to the British and
Turkish patients, who had variable neurological symp-
toms and findings, including muscular hypotonia, en-
cephalopathy, seizures, and Leigh syndrome, which are
typical for mitochondrial respiratory chain defects.
Since it was surprising that the complex III activity
seemed normal in the Finnish patients, we used all avail-
able material and methods to confirm it. For respiratory
chain enzyme activity measurements, fresh biopsy sam-
ples generally give the most reliable results, and we had
appropriate age-matched controls available for muscle
biopsy specimens. Enzyme activity measurements of
the muscle biopsy samples of the Finnish patients were
within the normal range (table 3), and oxygen con-
sumption studies have also previously implied normal
respiratory chain function in fresh muscle samples (Fell-
man et al. 1998). In one patient, analysis of the biopsy
sample showed normal enzyme activities, but direct
complex III measurement of the autopsy muscle sample
was in the lower part of the control range (table 5). If
this reduction is not a postmortem artifact due to a
tissue preservation problem and reduced enzyme activ-
ities, then the mild decrease may have remained unde-
tected in the indirect complex III analyses of the biopsy
specimen. Therefore, our data suggest that complex III
is not markedly affected in Finnish patients but cannot
exclude a mild defect. Partial reduction in the complex
III activity alone would not be likely to cause the severe
clinical picture of the Finnish patients, since the Turkish
patients (de Lonlay et al. 2001) with clearly decreased
complex III activities survived longer and were less
growth retarded than were the Finnish patients. How-
ever, even a mild complex III defect might contribute to
the lactic acidosis and other symptoms.
Nuclear gene defects causing mitochondrial disorders
often have a strictly tissue-specific expression (Papa-
dopoulou et al. 1999), and, in GRACILE syndrome, the
most relevant tissue for expressing complex III defi-
ciency is the liver, since it is the major organ of dys-
function. The enzyme activity measurements of the liver
specimens of the Finnish patients with GRACILE syn-
drome do not support complex III deficiency. The com-
plex III activity in the liver homogenate of one patient
(table 5) was comparable to that of the control indi-
viduals. Enzyme activity measurements of the isolated
mitochondria of the liver specimens of four patients,
obtained at autopsy shortly after death, also supported
this finding by showing the presence of complex III ac-
tivity, although, because there were so few control in-
dividuals, fully reliable conclusions regarding these sam-
ples are not possible. Thus, we consider it unlikely that
the Finnish patients with GRACILE syndrome have a
liver-specific complex III defect severe enough to result
in the fatal course of the disease.
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How could the S78G mutation disturb the other
function of BCS1L while leaving complex III activity
practically unaffected? The mutation is located be-
tween the transmembrane domain and the AAA do-
main of the BCS1L polypeptide. The function of this
region remains to be characterized and could poten-
tially be associated with this as-yet-uncharacterized
function of BCS1L (fig. 1B and 1C). Our pulse-chase
experiments also showed that the S78G mutation ac-
celerates degradation of the BCS1L polypeptide in vi-
tro. If this were also to result in decreased BCS1L
protein levels in tissues in vivo, without the mutation
interfering in protein conformation, then the reduced
protein amount in the mitochondria could possibly be
sufficient to perform complex III assembly, whereas the
other function could be compromised.
Rieske protein, which is joined to precomplex III by
BCS1p in yeast, contains an FeS cluster. FeS proteins
are essential in electron transport systems and in nu-
merous other cellular functions in the mitochondria,
cytosol, and nucleus. It is an intriguing questionwhether
BCS1L has a more general role in the biosynthesis or
transport of these proteins. Biosynthesis of the FeS clus-
ters is accomplished in mitochondria, and a dozen mi-
tochondrial proteins involved in the process have so far
been identified in S. cerevisiae (Muhlenhoff and Lill
2000).
Our yeast complementation studies showed that aer-
obic energy production in S78G transformants was de-
fective. This could be due either to complex III defi-
ciency, a defect in the respiratory chain in general, or
iron toxicity. However, the wild-type human BCS1L
was only partially able to complement the BCS1-dele-
tion yeast, and, therefore, the consequences of the S78G
mutation can appear more serious in yeast complemen-
tation experiments than they are in vivo. No significant
defects in respiratory chain complexes other than com-
plex III have been reported in patients with BCS1Lmu-
tations, although a slight, nonspecific decrease in com-
plex I has been observed in Finnish patients (Fellman
et al. 1998), and two British infants had slightly de-
creased complex IV activity in skeletal muscle (Morris
et al. 1995).
Until now, DNA diagnosis of GRACILE syndrome
has been possible in Finland, based on linkage analysis
in families with at least one affected child (Fellman et
al. 2002). Now the Finnish S78G mutation can be iden-
tified directly, which enables DNA diagnosis and genetic
counseling even for families without a previously af-
fected baby. For non-Finnish patients, sequence analysis
of the BCS1L gene is a diagnostic option.
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